Business
Evolus Reports Second Quarter 2024 Results and Raises Full Year Revenue Guidance
Total Net Revenue of $66.9 Million for Q2 2024, Up 36% from Q2 2023 Raises Full-Year 2024 Net Revenue Guidance to $260 Million to $270 Million, Representing
About this update from Evolus, Inc. Common Stock
[{"type":"text","content":"\n\nTotal Net Revenue of $66.9 Million for Q2 2024, Up 36% from Q2 2023\n\n\n\nRaises Full-Year 2024 Net Revenue Guidance to $260 Million to $270 Million, Representing Year-Over-Year Growth of 34% at the Top End\n\n\n\nImproved Quarterly GAAP Operating Loss to $7.7 Million; Delivered First Ever Quarter of Profitability1 with Positive Non-GAAP Operating Income of $1.1 Million for Q2 2024\n\n\n\nPremarket Approval (PMA) Application Submitted to the U.S. Food and Drug Administration (FDA) for Evolysse™ Lift and Evolysse™ Smooth Fillers, Approval and Launch Expected in Second Half of 2025\n\n\n\n NEWPORT BEACH, Calif.--(BUSINESS WIRE)--\nEvolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported financial results for the second quarter ended June 30, 2024, and provided a business update.\n\n\n“We are thrilled to have achieved quarterly profitability1 for the first time, driven by record revenue, demonstrating our continued strong execution and unwavering commitment to building a leadership position in the performance beauty industry,” said David Moatazedi, President and Chief Executive Officer. “With record quarterly revenue and all-time highs across key performance indicators, we are raising our full-year 2024 net revenue guidance to between $260 million and $270 million, equating to growth of over 30% for our fifth consecutive year since commercialization.”\n\n\n“As we advance toward achieving our 2028 revenue goal of at least $700 million, we are pleased with the continued strength of Jeuveau®, the ongoing expansion of our global footprint into the largest markets internationally, and the progress we’ve made in expanding our portfolio with the recent submission of the PMA to the FDA for our first two Evolysse™ dermal filler products,” Moatazedi continued. “We anticipate approval and launch of these fillers in the second half of 2025, along with the planned approval of the Estyme® dermal filler products in Europe in late 2024 and launch in 2025.”\n\n\nSecond Quarter 2024 Highlights and Recent Developments\n\n\n\nThe company’s key performance indicators maintained strong momentum during the second quarter.\n\n\nEvolus added 770 new customer accounts in the quarter, bringing the total number of customers purchasing since launch to approximately 14,000....